Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.

Samsung Bioepis' Q1 2025 report shows oncology, ophthalmology, and pegfilgrastim biosimilars have gained significant market share, while immunology, filgrastim, epoetin alfa, and insulin glargine ...

While most of its current revenue comes from the contract manufacturing business, Samsung Biologics aims to increase its exposure in the contract development organization business, which provides a ...

Samsung Biologics achieved record annual revenue of 4.55 trillion won in 2024, with a 23 percent increase year over year.

Samsung Biologics has made history by becoming the nation's first biotech company to hit 4 trillion won ($2.78 billion) in ...

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar ...

AbbVie (ABBV) continues to dominate the adalimumab market with 72% share in the U.S., despite biosimilar threats gaining ground. Read more here.

Marks the Third Year Since the Launch of the First US Biosimilar Market Report INCHEON, South Korea, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Co., Ltd. today released its First Quarter 2025 Biosimilar ...

As 2024 has come and passed, we saw another year of significant developments in litigation involving biologics and biosimilars. The ...

Samsung Bioepis and Teva have entered into a license, development and commercialization agreement for Epysqli ...